MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a pioneer in the biotechnology field, is set to hold an in-person Clinical Showcase on February 21, 2024, at the Nasdaq Market Site in Times Square, New York City. The event will offer a deep dive into the company’s innovative gene and cell therapies and vaccines.
A key highlight of the showcase will be the upcoming Phase 3 trial of OCU400, a potential breakthrough treatment for retinitis pigmentosa. Attendees will gain insights into the study design and the broad indication for this treatment. Additionally, updates from the ongoing Phase 1/2 trial of OCU400 will be shared, offering a glimpse into the therapy’s potential efficacy.
The event will also feature a panel discussion on the genesis of modifier gene therapy. This novel approach, which has evolved from lab theories to clinical application, could potentially revolutionize the treatment of multiple retinal diseases with a single product.
Leading the presentation will be Ocugen’s Chairman, CEO, and Co-founder, Dr. Shankar Musunuri, along with Mike Shine, SVP Commercial, and Dr. Arun Upadhyay, CSO & Head of R&D.
The panel will include luminaries such as Dr. Lejla Vajzovic of Duke Eye Center and Duke University School of Medicine, Dr. Byron Lam from the University of Miami, and Dr. Neena Haider, the inventor of modifier gene therapy and a faculty member at Harvard Medical School. A patient who has completed 12 months of therapy in the OCU400 Phase 1/2 clinical trial will also share their experience.
The Clinical Showcase represents an opportunity for healthcare professionals to better understand the promising frontier of gene therapy. As Ocugen continues to forge new paths in scientific innovation, events like these provide crucial insight into the potential future of disease treatment.
Advance registration is required for the event. Interested attendees can register by contacting Tiffany Hamilton at Tiffany.Hamilton@ocugen.com.
Ocugen, Inc. is a leading biotechnology company committed to discovering, developing, and commercializing novel gene and cell therapies and vaccines. The firm is making an impact on patient lives through courageous innovation—blazing new scientific trails that leverage its unique intellectual and human capital. Its groundbreaking modifier gene therapy platform holds promise for treating multiple retinal diseases with a single product. Ocugen is also advancing research in infectious and orthopedic diseases to address unmet medical needs.
In summary, Ocugen, Inc. is hosting an in-person Clinical Showcase on February 21, 2024, in New York City. The event will focus on their gene and cell therapies, including the Phase 3 trial of OCU400 for retinitis pigmentosa. The showcase will also feature a panel discussion on modifier gene therapy.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.